Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases

Molecular Endocrinology

Volumn 19, Issue 2, 2005, Pages 327-339

  Skildum, Andrew ^a   Faivre, Emily ^a   Lange, Carol A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR; GESTAGEN; GROWTH FACTOR; LIGAND; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROGESTERONE RECEPTOR; PROMEGESTONE; SERINE;

ARTICLE; BREAST CANCER; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION; UPREGULATION; WILD TYPE;

BINDING SITES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, SERUM-FREE; CYCLIN D1; DISEASE PROGRESSION; DOWN-REGULATION; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; LIGANDS; LUCIFERASES; MAP KINASE SIGNALING SYSTEM; MIFEPRISTONE; PHOSPHORYLATION; POINT MUTATION; PROGESTINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PROGESTERONE; S PHASE; SERINE; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; UP-REGULATION;

MINK CELL FOCUS-FORMING VIRUS;

EID: 13544276888     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2004-0306     Document Type: Article

References (76)

1. Raafat AM, Li S, Bennett JM, Hofseth LJ, Haslam SZ 2001 Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model. J Cell Physiol 187:81-89
2. Jordan VC 1990 Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res Treat 15:125-136
3. Jeng MH, Parker CJ, Jordan VC 1992 Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 52:6539-6546
4. Hissom JR, Moore MR 1987 Progestin effects on growth in the human breast cancer cell line T-47D - possible therapeutic implications. Biochem Biophys Res Commun 145:706-711
5. Hagley RD, Hissom JR, Moore MR 1987 Progestin stimulation of lactate dehydrogenase in the human breast cancer cell line T-47D. Biochim Biophys Acta 930:167-172
6. Sutherland RL, Hall RE, Pang GY, Musgrove EA, Clarke CL 1988 Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res 48:5084-5091
7. Kip1. Mol Endocrinol 11:1593-1607
8. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ 1999 Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84:4559-4565
9. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A, WHI Investigators 2003 Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289:3243-3253
10. Zhang Y, Beck CA, Poletti A, Edwards DP, Weigel NL 1995 Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol Endocrinol 9:1029-1040
11. Zhang Y, Beck CA, Poletti A, Clement IV JP, Prendergast P, Yip TT, Hutchens TW, Edwards DP, Weigel NL 1997 Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo. Mol Endocrinol 11:823-832
12. Knotts TA, Orkiszewski RS, Cook RG, Edwards DP, Weigel NL 2001 Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites. J Biol Chem 276:8475-8483
13. Lange CA, Shen T, Horwitz KB 2000 Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 97:1032-1037
14. Abdel-Hafiz H, Takimoto GS, Tung L, Horwitz KB 2002 The inhibitory function in human progesterone receptor N termini binds SUMO-1 protein to regulate autoinhibition and transrepression. J Biol Chem 277:33950-33956
15. Shao R, Zhang FP, Rung E, Palvimo JJ, Huhtaniemi I, Billig H 2004 Inhibition of small ubiquitin-related modifier-1 expression by luteinizing hormone receptor stimulation is linked to induction of progesterone receptor during ovulation in mouse granulosa cells. Endocrinology 145:384-392
16. Takimoto GS, Tung L, Abdel-Hafiz H, Abel MG, Sartorius CA, Richer JK, Jacobsen BM, Bain DL, Horwitz KB 2003 Functional properties of the N-terminal region of progesterone receptors and their mechanistic relationship to structure. J Steroid Biochem Mol Biol 85:209-219
17. Shen T, Horwitz KB, Lange CA 2001 Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol 21:6122-6131
18. Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA 2003 Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol 17:628-642
19. Horwitz KB, Wei LL, Sedlacek SM, d'Arville CN 1985 Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog Horm Res 41:249-316
20. Chauchereau A, Georgiakaki M, Perrin-Wolff M, Milgrom E, Loosfelt H 2000 JAB1 interacts with both the progesterone receptor and SRC-1. J Biol Chem 275:8540-8548
21. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB 1998 Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem 273:10696-10701
22. Bamberger AM, Bamberger CM, Gellersen B, Schulte HM 1996 Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells. Proc Natl Acad Sci USA 93:6169-6174
23. Wardell SE, Boonyaratanakornkit V, Adelman JS, Aronheim A, Edwards DP 2002 Jun dimerization protein 2 functions as a progesterone receptor N-terminal domain coactivator. Mol Cell Biol 22:5451-5466
24. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP 2001 Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 8:269-280
25. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F 1998 Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 17:2008-2018
26. Lange CA, Richer JK, Shen T, Horwitz KB 1998 Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 273:31308-31316
27. Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, Pestell RG 1995 Transforming p21 ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 270:23589-23597
28. Tetsu O, McCormick F1999 β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426
29. Moore MR, Conover JL, Franks KM 2000 Progestin effects on long-term growth, death, and Bcl-xL in breast cancer cells. Biochem Biophys Res Commun 277:650-654
30. Musgrove EA, Lee CS, Sutherland RL 1991 Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor a, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 11:5032-5043
31. Sutherland RL, Prall OW, Watts CK, Musgrove EA 1998 Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia 3:63-72
32. Musgrove EA, Lee CS, Cornish AL, Swarbrick A, Sutherland RL 1997 Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 11:54-66
33. Hagley RD, Moore MR 1985 A progestin effect on lactate dehydrogenase in the human breast cancer cell line T-47D. Biochem Biophys Res Commun 128:520-524
34. Greene GL, Harris K, Bova R, Kinders R, Moore B, Nolan C 1988 Purification of T47D human progesterone receptor and immunochemical characterization with monoclonal antibodies. Mol Endocrinol 2:714-726
35. Qiu M, Lange CA 2003 MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. J Steroid Biochem Mol Biol 85:147-157
36. Bowden RT, Hissom JR, Moore MR 1989 Growth stimulation of T47D human breast cancer cells by the antiprogestin RU486. Endocrinology 124:2642-2644
37. Iwasaki K, Underwood B, Herman M, Dinda S, Kodali S, Kloosterboer HJ, Hurd C, Moudgil VK 1999 Effects of antiprogestins on the rate of proliferation of breast cancer cells. Mol Cell Biochem 198:141-149
38. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ 1999 The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18:1571-1583
39. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M 1995 Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15:2612-2624
40. Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J 1994 Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 9:707-718
41. Tsai LH, Lees E, Faha B, Harlow E, Riabowol K 1993 The cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene 8:1593-1602
42. Giordano A, Whyte P, Harlow E, Franza Jr BR, Beach D, Draetta G 1989 A 60 kd cdc2-associated polypeptide complexes with the E1A proteins in adenovirus-infected cells. Cell 58:981-990
43. Hunter T, Pines J 1991 Cyclins and cancer. Cell 66:1071-1074
44. Neve RM, Holbro T, Hynes NE 2002 Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 21:4567-4576
45. Beck CA, Zhang Y, Weigel NL, Edwards DP 1996 Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem 271:1209-1217
46. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP 1993 The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci USA 90:4441-4445
47. Chalbos D, Galtier F, Emiliani S, Rochefort H 1991 The anti-progestin RU486 stabilizes the progestin-induced fatty acid synthetase mRNA but does not stimulate its transcription. J Biol Chem 266:8220-8224
48. Pasapera AM, Camacho-Arroyo I, Savouret JF, Garcia GA, Perez-Palacios G, Pichon C, Cerbon MA 1995 In vitro molecular assessment of the mechanisms of action of 19-nor progestins used as contragestational agents. Arch Med Res 26 Spec No:S203-S207
49. el-Ashry D, Onate SA, Nordeen SK, Edwards DP 1989 Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form. Mol Endocrinol 3:1545-1558
50. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA, Senderowicz AM 1999 Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59:4634-4641
51. Dufourny B, van Teeffelen HA, Hamelers IH, Sussenbach JS, Steenbergh PH 2000 Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells. J Endocrinol 166:329-338
52. Lin S, Wang W, Wilson GM, Yang X, Brewer G, Holbrook NJ, Gorospe M 2000 Down-regulation of cyclin D1 expression by prostaglandin A(2) is mediated by enhanced cyclin D1 mRNA turnover. Mol Cell Biol 20:7903-7913
53. Zou Y, Ewton DZ, Deng X, Mercer SE, Friedman E 2004 Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J Biol Chem 279:27790-27798
54. Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu ML, Takano E, Maki M, Henkart PA, Trepel JB 1997 Regulation of cyclin D1 by calpain protease. J Biol Chem 272:28479-28484
55. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV 2003 Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17:575-588
56. Lange CA, Richer JK, Horwitz KB 1999 Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 13:829-836
57. Song RX, Santen RJ, Kumar R, Adam L, Jeng MH, Masamura S, Yue W 2002 Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells. Mol Cell Endocrinol 193:29-42
58. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Yue W, Berstein L 2003 Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr Relat Cancer 10:111-130
59. Pawlowski V, Revillion F, Hebbar M, Hornez L, Peyrat JP 2000 Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6:4217-4225
60. Walker RA, Dearing SJ 1999 Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 53:167-176
61. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
62. Lange CA 2004 Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word? Mol Endocrinol 18:269-278
63. Welshons WV, Wolf MF, Murphy CS, Jordan VC 1988 Estrogenic activity of phenol red. Mol Cell Endocrinol 57:169-178
64. Hunter T, Pines J 1994 Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 79:573-582
65. Sherr CJ 1996 Cancer cell cycles. Science 274:1672-1677
66. Sicinski P, Weinberg RA 1997 A specific role for cyclin D1 in mammary gland development. J Mammary Gland Biol Neoplasia 2:335-342
67. Fantl V, Edwards PA, Steel JH, Vonderhaar BK, Dickson C 1999 Impaired mammary gland development in Cyl1(-/-) mice during pregnancy and lactation is epithelial cell autonomous. Dev Biol 212:1-11
68. Lydon JP, DeMayo FJ, Conneely OM, O'Malley BW 1996 Reproductive phenotpes of the progesterone receptor null mutant mouse. J Steroid Biochem Mol Biol 56:67-77
69. Hsiang CH, Straus DS 2002 Cyclopentenone causes cell cycle arrest and represses cyclin D1 promoter activity in MCF-7 breast cancer cells. Oncogene 21:2212-2226
70. Lobenhofer EK, Huper G, Iglehart JD, Marks JR 2000 Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ 11:99-110
71. Marino M, Acconcia F, Trentalance A 2003 Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol Biol Cell 14:2583-2591
72. Guillemot L, Levy A, Raymondjean M, Rothhut B 2001 Angiotensin II-induced transcriptional activation of the cyclin D1 gene is mediated by Egr-1 in CHO-AT(1A) cells. J Biol Chem 276:39394-39403
73. Tong W, Pollard JW 1999 Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. Mol Cell Biol 19:2251-2264
74. Moore MR, Hathaway LD, Bircher JA 1991 Progestin stimulation of thymidine kinase in the human breast cancer cell line T47D. Biochim Biophys Acta 1096:170-174
75. Moore MR 2004 A rationale for inhibiting progesterone-related pathways to combat breast cancer. Curr Cancer Drug Targets 4:183-189
76. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, Horwitz KB 1994 New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 54:3868-3877